ISTOCK, JUANMONINO
Traitorous Tumor Cells Kill Their Own Kind
Traitorous Tumor Cells Kill Their Own Kind
Researchers plan to turn cancer cells into defectors, engineering them to kill the tumors from whence they came, and have tested the approach in mice.
Traitorous Tumor Cells Kill Their Own Kind
Traitorous Tumor Cells Kill Their Own Kind

Researchers plan to turn cancer cells into defectors, engineering them to kill the tumors from whence they came, and have tested the approach in mice.

Researchers plan to turn cancer cells into defectors, engineering them to kill the tumors from whence they came, and have tested the approach in mice.

cancer therapeutics
Poliovirus Therapy May Extend Lives of Advanced Brain-Cancer Patients
Poliovirus Therapy May Extend Lives of Advanced Brain-Cancer Patients
Ashley Yeager | Jun 26, 2018
More than one-fifth of individuals treated with the genetically modified virus survived at least three years.
A T-Cell Tweak Combats Advanced Breast Cancer
A T-Cell Tweak Combats Advanced Breast Cancer
Ashley Yeager | Jun 5, 2018
The immunotherapy eliminated a woman’s metastatic lesions and kept her disease-free for two years.
World’s Largest Cell and Gene Therapy Plant Opens
World’s Largest Cell and Gene Therapy Plant Opens
Catherine Offord | Apr 11, 2018
Lonza will employ more than 200 full-time staff to work at the Texas-based facility, the company says.
Human Cancer Drugs May Be Effective in Tasmanian Devils
Human Cancer Drugs May Be Effective in Tasmanian Devils
Shawna Williams | Apr 9, 2018
A new study reveals similarities between the transmissible cancers that infect the endangered marsupials, and hints at ways to treat them.
OSU Professor Falsified Data on Eight Papers, Resigns
OSU Professor Falsified Data on Eight Papers, Resigns
Catherine Offord | Apr 2, 2018
Ching-Shih Chen’s research involved anticancer therapeutics that were being tested in clinical trials.
A Radical Intervention, 1894
A Radical Intervention, 1894
Catherine Offord | Apr 1, 2018
William Halsted’s approach to mastectomy took the medical world by storm at the turn of the last century.
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
Ilana Chefetz Confronts Ovarian Cancer
Ilana Chefetz Confronts Ovarian Cancer
Jim Daley | Apr 1, 2018
The University of Minnesota researcher is on the front lines in the fight against the disease.
Mutant RAS Proteins Team Up for Oncogenicity
Mutant RAS Proteins Team Up for Oncogenicity
Jim Daley | Apr 1, 2018
Mice with cancer whose KRAS proteins couldn’t link together had much better survival outcomes than those whose oncogenic mutant paired with wild-type KRAS.